Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Genuine Parts Company (GPC) vs Novavax Inc (NVAX) Price & Performance

Genuine Parts CompanyTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Genuine Parts Company vs Novavax Inc — how do they compare? Genuine Parts Company trades at $125.22 (market cap $16.65B), while Novavax Inc trades at $8.29 (market cap $1.39B). The key difference: Genuine Parts Company is far larger — about 12× Novavax Inc's market cap, and Genuine Parts Company pays a 3.51% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

GPCNVAX
Market Cap
$16.65B$1.39B
Sector
Consumer CyclicalHealth
52-Week High
$149.26$11.19
52-Week Low
$92.47$6.22
Enterprise Value
$22.87B$890.94M
Dividend Yield
3.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Genuine Parts Company

Genuine Parts Company (GPC) trades at $122.16, down 1.1% on the day, with a bullish technical signal supported by moving averages and oscillators. Fundamentally, the company shows strong revenue growth to $24.3B in 2025 but faces significant margin compression, with net income plummeting to $66M (0.27% margin) from $904M the prior year. The stock carries a high P/E of 275 but reasonable P/S of 0.68, while analysts maintain a consensus 'Buy' rating with a $133 price target. Recent news highlights GPC's upcoming Q2 2026 earnings report on July 21, 2026, and its status as a Dividend King with 70 consecutive years of dividend increases.

The outlook presents a mixed picture: technical strength and dividend reliability support the stock, while deteriorating profitability and high valuation multiples pose significant risks. Investment opportunity lies in potential earnings recovery and continued dividend growth, but investors face headwinds from margin pressure and elevated P/E ratio requiring careful monitoring of upcoming quarterly results.

Novavax Inc

Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.

The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.

Returns comparison

Trailing returns across standard periods

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX